Clinical outcomes in patients with BRAFV600 mutant melanoma and undetectable circulating tumor DNA treated with dabrafenib and trametinib.

被引：0
|
作者：
Algazi, Alain Patrick
Othus, Megan
Voorhies, Benjamin Newell
Kendra, Kari Lynn
Dakhil, Shaker R.
Harker-Murray, Amy K.
Lao, Christopher D.
Chmielowski, Bartosz
Lo, Roger
Grossmann, Kenneth F.
Ribas, Antoni
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[3] Hunstman Canc Inst, Herriman, UT USA
[4] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Columbus, OH 43210 USA
[5] Wichita NCORP, Wichita, KS USA
[6] Med Coll Wisconsin, Pewaukee, WI USA
[7] Univ Michigan, Ann Arbor, MI 48109 USA
[8] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[9] Univ Calif Los Angeles, Los Angeles, CA USA
[10] Huntsman Canc Inst, Salt Lake City, UT USA
[11] Univ Calif Los Angeles, Ctr Comprehens Canc, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10059
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations
    Spain, Lavinia
    Julve, Maximilian
    Larkin, James
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (07) : 1031 - 1038
  • [2] Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAFV600 Mutation
    Sohita Dhillon
    [J]. Targeted Oncology, 2016, 11 : 417 - 428
  • [3] Effectiveness of Dabrafenib plus Trametinib during the Treatment of Melanoma Patients with BRAFV600 mutated Brain Metastases
    Berking, C.
    Schadendorf, D.
    Weichenthal, M.
    Eigentler, T.
    Schober, K.
    Mohr, P.
    Kiecker, F.
    Loquai, C.
    Debus, D.
    Gutzmer, R.
    Leiter-Stoeppke, U.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 80 - 81
  • [4] The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib.
    McQuade, Jennifer Leigh
    Haydu, Lauren Elaine
    Frankian, Silva
    Spencer, Christine
    Long, Georgina V.
    Grob, Jean Jacques
    Lane, Stephen R.
    Legenne, Philippe
    Flaherty, Keith
    Hwu, Patrick
    Hess, Kenneth R.
    Davies, Michael A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib
    Aglietta, Massimo
    Chiarion-Sileni, Vanna
    Fava, Paolo
    Guidoboni, Massimo
    Depenni, Roberta
    Minisini, Alessandro
    Consoli, Francesca
    Ascierto, Paolo Antonio
    Rinaldi, Gaetana
    Banzi, Maria
    Marconcini, Riccardo
    Gueli, Rossana
    Ferraresi, Virginia
    Tucci, Marco
    Tonini, Giuseppe
    Lo Re, Giovanni
    Guida, Michele
    Del Vecchio, Michele
    Marcon, Ilaria Gioia
    Queirolo, Paola
    [J]. TUMORI JOURNAL, 2023, 109 (06): : 537 - 545
  • [6] A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)
    Dayimu, Alimu
    Gupta, Avinash
    Matin, Rubeta N.
    Nobes, Jenny
    Board, Ruth
    Payne, Miranda
    Rao, Ankit
    Fusi, Alberto
    Danson, Sarah
    Eccles, Bryony
    Carser, Judith
    Brown, Ciara O'Hanlon
    Steven, Neil
    Bhattacharyya, Madhumita
    Brown, Ewan
    Gonzalez, Michael
    Highley, Martin
    Pickering, Lisa
    Kumar, Satish
    Waterston, Ashita
    Burghel, George
    Demain, Leigh
    Baker, Eleanor
    Wulff, Jerome
    Qian, Wendi
    Twelves, Sophie
    Middleton, Mark
    Corrie, Pippa
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 196
  • [7] Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
    Syeda, Mahrukh M.
    Wiggins, Jennifer M.
    Corless, Broderick C.
    Long, Georgina, V
    Flaherty, Keith T.
    Schadendorf, Dirk
    Nathan, Paul D.
    Robert, Caroline
    Ribas, Antoni
    Davies, Michael A.
    Grob, Jean Jacques
    Gasal, Eduard
    Squires, Matthew
    Marker, Mahtab
    Garrett, James
    Brase, Jan C.
    Polsky, David
    [J]. LANCET ONCOLOGY, 2021, 22 (03): : 370 - 380
  • [8] Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma
    Lu, William
    Burton, Luciana
    Larkin, James
    Chapman, Paul B.
    Ascierto, Paolo A.
    Ribas, Antoni
    Robert, Caroline
    Sosman, Jeffrey A.
    McArthur, Grant A.
    Chang, Ilsung
    Caro, Ivor
    Penuel, Elicia
    Yan, Yibing
    Wongchenko, Matthew J.
    [J]. JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 17
  • [9] BRAFV600 mutation in circulating tumor DNA can predict outcomes in early-stage melanoma.
    Gouda, Mohamed Alaa
    Polivka, Jiri
    Huang, Helen
    Treskova, Inka
    Pivovarcikova, Kristyna
    Meric-Bernstam, Funda
    Pesta, Martin
    Janku, Filip
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [10] Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
    Isberner, Nora
    Gesierich, Anja
    Balakirouchenane, David
    Schilling, Bastian
    Aghai-Trommeschlaeger, Fatemeh
    Zimmermann, Sebastian
    Kurlbaum, Max
    Puszkiel, Alicja
    Blanchet, Benoit
    Klinker, Hartwig
    Scherf-Clavel, Oliver
    [J]. CANCERS, 2022, 14 (19)
12345